Research
Hormonal
Obesity is associated with altered nutrient sensing mechanisms in the gut, specifically region-dependent changes in the expression of amino acid and bitter taste receptors, which may contribute to inconsistent gut hormone fluctuations.
In obesity, the gut's ability to sense nutrients like proteins and fats changes depending on the location in the gut. This altered sensing contributes to why hormone signals (like GLP-1 or PYY) might not work as expected in obese individuals compared to lean ones.
ModerateQualifiesMEDIUM confidence
The expression of amino acid sensors and bitter taste receptors in the mucosa of the human stomach and small intestine is affected by obesity in a region-dependent manner [73,74].
Why this rating
Based on in vitro and in vivo studies showing region-dependent changes, but clinical consistency varies.
Source
The Function of Gastrointestinal Hormones in Obesity—Implications for the Regulation of Energy Intake
Mona Farhadipour et al. · Nutrients · 2021
DOI 10.3390/nu13061839
narrative_reviewCited 55×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Roux-en-Y gastric bypass (RYGB) surgery restores gut hormone balance by elevating postprandial GLP-1 and PYY levels, which contributes to sustained weight loss and improved glucose homeostasis.Good
- Combination therapy using GLP-1 receptor agonists with other hormones (GIP, GCG, or PYY) mimics the beneficial hormonal effects of gastric bypass surgery in non-surgical patients.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →